Loading...
XNAS
BCTXW
Market cap13mUSD
Jul 14, Last price  
0.05USD
1D
-29.90%
1Q
-48.31%
IPO
-93.47%
Name

Briacell Therapeutics Corp

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
95.26%
Rev. gr., 5y
%
Revenues
0k
Net income
-5m
L-76.40%
000000000000000-2,894,643-11,580,692-20,302,394-4,791,466
CFO
-24m
L+1.61%
000000000000000-7,747,651-12,484,376-23,744,860-24,126,128

Profile

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
URL
https://briacell.com/
IPO date
Oct 12, 2006
Employees
5
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑072015‑07
Income
Revenues
Cost of revenue
33,330
23,272
15,289
Unusual Expense (Income)
NOPBT
(33,330)
(23,272)
(15,289)
NOPBT Margin
Operating Taxes
(153)
31
Tax Rate
NOPAT
(33,330)
(23,120)
(15,320)
Net income
(4,791)
-76.40%
(20,302)
75.31%
(11,581)
300.07%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,419
3,953
(10,172)
BB yield
-26.07%
-2.93%
7.89%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
1,096
29,139
31,307
Net debt
(1,281)
(21,251)
(41,042)
Cash flow
Cash from operating activities
(24,126)
(23,745)
(12,484)
CAPEX
(457)
Cash from investing activities
(682)
Cash from financing activities
4,419
3,954
(3,743)
FCF
(26,034)
(26,633)
(15,671)
Balance
Cash
862
21,251
41,042
Long term investments
418
2
2
Excess cash
1,281
21,251
41,042
Stockholders' equity
(13,718)
(11,199)
5,101
Invested Capital
12,130
36,561
36,535
ROIC
ROCE
2,097.69%
EV
Common stock shares outstanding
16,455
15,518
15,518
Price
1.03
-88.13%
8.68
4.45%
8.31
30.66%
Market cap
16,949
-87.42%
134,696
4.45%
128,955
32.79%
EV
15,365
113,445
87,913
EBITDA
(33,246)
(23,257)
(15,274)
EV/EBITDA
Interest
979
Interest/NOPBT